# Complete Response Case of Metastatic Hormone-Sensitive Prostate Cancer Treated With Triplet Therapy (Androgen Deprivation Therapy + Docetaxel + Darolutamide)

## TL;DR

A 69-year-old man with advanced prostate cancer achieved a complete response using a combination therapy of androgen deprivation, docetaxel, and darolutamide.

## Contribution

This case highlights the potential of triplet therapy in achieving complete remission in metastatic hormone-sensitive prostate cancer.

## Key findings

- The patient's PSA levels dropped to undetectable levels within five months of starting triplet therapy.
- Bone scan index normalized 13 months after treatment initiation, indicating complete response.
- Regular radiological monitoring is essential to confirm treatment efficacy alongside PSA testing.

## Abstract

In this work, we report a complete response case of a 69-year-old male with metastatic prostate cancer (initial prostate-specific antigen (PSA)=26.3 ng/mL, Gleason score 3+4=7, cT3a, N0, M1b) treated with triplet therapy comprising leuprorelin + docetaxel (75 mg/m2/3 weeks) + darolutamide (1,200 mg/d). His PSA was checked monthly, and radiological scans (computed tomography and bone scans) were administered every three months. His PSA declined quickly, reaching <0.01 ng/mL five months after starting triplet therapy, but his bone scan index declined gradually, reaching 0.0% 13 months after starting triplet therapy. To evaluate the true efficacy of triplet therapy, regular radiological testing should be performed, similar to regular PSA testing.